25 Years of salmon calcitonin: From synthesis to therapeutic use

ConclusionAlthough calcitonin has an established place in the treatment of Paget's disease of bone and certain disorders of calcium homeostasis, its most exciting clinical application is in the management of postmenopausal and senile osteoporosis. This disorder affects a vast number of women and, with the increasingly aging population, imposes a heavy burden on health care systems. Although other therapies for osteoporosis and other disorders of bone turnover (e.g., bisphosphonates, fluoride) are in use, many questions remain to be answered concerning their side effects and long-term safety, whereas salmon calcitonin is of proven safety. The introduction of salmon calcitonin nasal spray is a significant therapeutic advance, and the development of other noninjectable preparations will further increase the acceptability of calcitonin to patients and physicians alike.

[1]  A. Pearse,et al.  Cytochemical Evidence for an Ultimobranchial Origin of Rodent Thyroid C Cells , 1967, Nature.

[2]  J. Ringe,et al.  Salmon calcitonin in the therapy of corticoid-induced osteoporosis , 2004, European Journal of Clinical Pharmacology.

[3]  R. O'dor,et al.  Amino acid composition of salmon calcitonin. , 1969, Canadian journal of biochemistry.

[4]  O. Johnell,et al.  Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. , 1992, BMJ.

[5]  J. Reginster,et al.  A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. , 1995, The American journal of medicine.

[6]  B. Riis,et al.  Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. , 1990, The American journal of medicine.

[7]  P. L. Munson,et al.  THYROID HYPOCALCEMIC PRINCIPLE AND RECURRENT LARYNGEAL NERVE INJURY AS FACTORS AFFECTING THE RESPONSE TO PARATHYROIDECTOMY IN RATS. , 1963, Endocrinology.

[8]  F. Singer,et al.  Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. , 1980, Arthritis and rheumatism.

[9]  H. Sjöberg,et al.  Acute treatment with calcitonin in primary hyperparathyroidism and severe hypercalcaemia of other origin. , 1975, Acta chirurgica Scandinavica.

[10]  S. Guttmann,et al.  Synthese von Salm‐Calcitonin, einem hochaktiven hypocalcämischen Hormon. Vorläufige Mitteilung , 1969 .

[11]  I. Macintyre,et al.  FURTHER EVIDENCE FOR CALCITONIN. A RAPID-ACTING HORMONE WHICH LOWERS PLASMA-CALCIUM. , 1963, Lancet.

[12]  T. Chambers,et al.  The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. , 1983, The Journal of clinical endocrinology and metabolism.

[13]  D. Copp,et al.  Evidence for calcitonin--a new hormone from the parathyroid that lowers blood calcium. , 1962, Endocrinology.

[14]  M. A. Hansen,et al.  Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. , 1992, BMJ.

[15]  S. Wallach,et al.  Effects of calcitonin on bone quality and osteoblastic function , 1993, Calcified Tissue International.

[16]  M. Revilla,et al.  Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. , 1992, Bone and mineral.

[17]  M. Azria.  The Calcitonins: Physiology and Pharmacology , 1989 .

[18]  Copp Dh.  Calcitonin : discovery, development, and clinical application , 1994 .

[19]  B. Riis,et al.  Effect of salcatonin given intranasally on early postmenopausal bone loss. , 1989, BMJ.

[20]  K. Pun,et al.  Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. , 1989, Clinical therapeutics.

[21]  H. Becker,et al.  Inhibition of gastrin release and gastric secretion by calcitonin in patients with peptic ulcer. , 1974, American journal of surgery.

[22]  Chang Lw,et al.  Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. , 1989 .

[23]  S. Wallach,et al.  Treatment of Paget's disease with calcitonin. , 1972, Seminars in drug treatment.

[24]  P. Corran,et al.  International Standards for salmon calcitonin, eel calcitonin, and the Asu1-7 analogue of eel calcitonin: calibration by international collaborative study. , 1990, Bone and mineral.

[25]  A. Fitton,et al.  Intranasal Salmon Calcitonin , 1991 .

[26]  Y. Nishi,et al.  Effect of long-term calcitonin therapy by injection and nasal spray on the incidence of fractures in osteogenesis imperfecta. , 1992, The Journal of pediatrics.

[27]  M. Passeri,et al.  SIDE-EFFECTS OF SYNTHETIC SALMON AND HUMAN CALCITONIN , 1983, The Lancet.

[28]  F. López-Soriano,et al.  Postoperative analgesia induced by subarachnoid lidocaine plus calcitonin. , 1987, Anesthesia and Analgesia.

[29]  S. Krane,et al.  An evaluation of antibodies and clinical resistance to salmon calcitonin. , 1972, The Journal of clinical investigation.

[30]  L. Avioli,et al.  Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. , 1988, The Journal of clinical investigation.

[31]  H. Keutmann,et al.  Amino acid sequence of salmon ultimobranchial calcitonin. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Cockcroft,et al.  Calcitonin from Ultimobranchial Glands of Dogfish and Chickens , 1967, Science.

[33]  J. Reginster,et al.  Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. , 1990, Scandinavian journal of rheumatology.

[34]  C. Christiansen,et al.  NASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSIS , 1989, Clinical endocrinology.